Xbiotech Stock Performance
| XBIT Stock | USD 2.45 0.08 3.38% |
XBiotech has a performance score of 1 on a scale of 0 to 100. The firm maintains a market beta of 1.93, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, XBiotech will likely underperform. XBiotech right now maintains a risk of 3.45%. Please check out XBiotech semi variance, and the relationship between the treynor ratio and daily balance of power , to decide if XBiotech will be following its historical returns.
Risk-Adjusted Performance
Weak
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in XBiotech are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively stable forward indicators, XBiotech is not utilizing all of its potentials. The latest stock price uproar, may contribute to short-horizon losses for the private investors. ...more
Actual Historical Performance (%)
One Day Return 3.38 | Five Day Return 4.7 | Year To Date Return 2.94 | Ten Year Return (70.48) | All Time Return (89.46) |
Dividend Date 2021-07-23 | Ex Dividend Date 2021-07-15 |
1 | Is XBiotech Inc. stock a top hedge fund pick - Quarterly Earnings Summary High Yield Equity Trading Tips - newser.com | 11/18/2025 |
2 | How XBiotech Inc. stock gains from tech spending - 2025 Earnings Surprises Detailed Earnings Play Alerts - | 12/18/2025 |
3 | CEO Moves Will XBIT stock rally after Fed decisions - IPO Watch Detailed Earnings Play Strategies - moha.gov.vn | 12/29/2025 |
4 | XBiotech Shares Pass Above 50-Day Moving Average - Heres What Happened - MarketBeat | 01/23/2026 |
5 | Acquisition by Sushma Shivaswamy of 100000 shares of XBiotech at 3.84 subject to Rule 16b-3 | 01/29/2026 |
6 | Disposition of 1173033 shares by Bay Street Financial S.a. of XBiotech at 18.78 subject to Rule 16b-3 | 02/04/2026 |
7 | XBiotech Stock Price Passes Below 50-Day Moving Average - Time to Sell - MarketBeat | 02/10/2026 |
| Begin Period Cash Flow | 200 M | |
| Total Cashflows From Investing Activities | -1.3 M |
XBiotech Relative Risk vs. Return Landscape
If you would invest 247.00 in XBiotech on November 16, 2025 and sell it today you would lose (2.00) from holding XBiotech or give up 0.81% of portfolio value over 90 days. XBiotech is currently generating 0.0446% in daily expected returns and assumes 3.4512% risk (volatility on return distribution) over the 90 days horizon. In different words, 31% of stocks are less volatile than XBiotech, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
XBiotech Target Price Odds to finish over Current Price
The tendency of XBiotech Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 2.45 | 90 days | 2.45 | about 58.48 |
Based on a normal probability distribution, the odds of XBiotech to move above the current price in 90 days from now is about 58.48 (This XBiotech probability density function shows the probability of XBiotech Stock to fall within a particular range of prices over 90 days) .
XBiotech Price Density |
| Price |
Predictive Modules for XBiotech
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as XBiotech. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.XBiotech Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. XBiotech is not an exception. The market had few large corrections towards the XBiotech's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold XBiotech, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of XBiotech within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.04 | |
β | Beta against Dow Jones | 1.93 | |
σ | Overall volatility | 0.14 | |
Ir | Information ratio | 0 |
XBiotech Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of XBiotech for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for XBiotech can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| XBiotech had very high historical volatility over the last 90 days | |
| Net Loss for the year was (38.53 M) with profit before overhead, payroll, taxes, and interest of 3.36 M. | |
| XBiotech currently holds about 225.79 M in cash with (30.96 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.42, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| XBiotech has a poor financial position based on the latest SEC disclosures | |
| Roughly 37.0% of the company outstanding shares are owned by insiders | |
| Latest headline from news.google.com: XBiotech Stock Price Passes Below 50-Day Moving Average - Time to Sell - MarketBeat |
XBiotech Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of XBiotech Stock often depends not only on the future outlook of the current and potential XBiotech's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. XBiotech's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 30.5 M | |
| Cash And Short Term Investments | 172.7 M |
XBiotech Fundamentals Growth
XBiotech Stock prices reflect investors' perceptions of the future prospects and financial health of XBiotech, and XBiotech fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on XBiotech Stock performance.
| Return On Equity | -0.16 | ||||
| Return On Asset | -0.11 | ||||
| Current Valuation | (89.56 M) | ||||
| Shares Outstanding | 30.49 M | ||||
| Price To Earning | 1.21 X | ||||
| Price To Book | 0.44 X | ||||
| Price To Sales | 12.23 X | ||||
| Gross Profit | 3.36 M | ||||
| EBITDA | (36.01 M) | ||||
| Net Income | (38.53 M) | ||||
| Cash And Equivalents | 225.79 M | ||||
| Cash Per Share | 7.42 X | ||||
| Total Debt | 10.25 M | ||||
| Debt To Equity | 0.06 % | ||||
| Current Ratio | 28.99 X | ||||
| Book Value Per Share | 5.48 X | ||||
| Cash Flow From Operations | (30.96 M) | ||||
| Earnings Per Share | (0.95) X | ||||
| Market Capitalization | 72.26 M | ||||
| Total Asset | 199.09 M | ||||
| Retained Earnings | (90.84 M) | ||||
| Working Capital | 159.46 M | ||||
| Current Asset | 93.04 M | ||||
| Current Liabilities | 6.29 M | ||||
About XBiotech Performance
Assessing XBiotech's fundamental ratios provides investors with valuable insights into XBiotech's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the XBiotech is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.17) | (0.18) | |
| Return On Capital Employed | (0.21) | (0.22) | |
| Return On Assets | (0.17) | (0.18) | |
| Return On Equity | (0.19) | (0.20) |
Things to note about XBiotech performance evaluation
Checking the ongoing alerts about XBiotech for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for XBiotech help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| XBiotech had very high historical volatility over the last 90 days | |
| Net Loss for the year was (38.53 M) with profit before overhead, payroll, taxes, and interest of 3.36 M. | |
| XBiotech currently holds about 225.79 M in cash with (30.96 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.42, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| XBiotech has a poor financial position based on the latest SEC disclosures | |
| Roughly 37.0% of the company outstanding shares are owned by insiders | |
| Latest headline from news.google.com: XBiotech Stock Price Passes Below 50-Day Moving Average - Time to Sell - MarketBeat |
- Analyzing XBiotech's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether XBiotech's stock is overvalued or undervalued compared to its peers.
- Examining XBiotech's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating XBiotech's management team can have a significant impact on its success or failure. Reviewing the track record and experience of XBiotech's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of XBiotech's stock. These opinions can provide insight into XBiotech's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for XBiotech Stock Analysis
When running XBiotech's price analysis, check to measure XBiotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy XBiotech is operating at the current time. Most of XBiotech's value examination focuses on studying past and present price action to predict the probability of XBiotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move XBiotech's price. Additionally, you may evaluate how the addition of XBiotech to your portfolios can decrease your overall portfolio volatility.